The Utility of Immunohistochemistry in the Differential Diagnosis of Gynecologic Disorders
- 1 January 2015
- journal article
- research article
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 139 (1), 39-54
- https://doi.org/10.5858/arpa.2014-0057-ra
Abstract
Context: Immunohistochemistry has assumed an increasing role in the identification and characterization of gynecologic disorders including lesions with deceptively bland morphology, uncommon and underdiagnosed neoplasms, and neoplasms with specific genetic alterations associated with overexpression or loss of expression of specific proteins. The diagnostic accuracy has been significantly improved owing to the discovery and increasing experience with the tumor-associated biomarkers, and the increasing demand for precise tumor classification to assess suitability for the expanding therapeutic modalities including clinical trials.Objective: To differentiate lesions of the gynecologic tract through the use of effective immunohistochemical panels.Data Sources: Literature review and authors' personal practice experience.Conclusions: The application of diagnostic and prognostic immunohistochemical panels has enabled pathologists to better guide therapeutic decisions and to better predict the clinical outcome. It is now well established that the use of ancillary testing, including immunohistochemistry, has a significant power in the identification, differentiation, and classification of reactive, premalignant, and malignant gynecologic disorders. This article discusses the utilities and pitfalls of the commonly used immunohistochemical markers in the context of overlapping morphologic features encountered in the uterus, ovaries, and fallopian tubes.This publication has 173 references indexed in Scilit:
- A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancerProceedings of the National Academy of Sciences of the United States of America, 2012
- Vascular Endothelial Growth Factor Receptor 2 as a Marker for Malignant Vascular Tumors and MesotheliomaThe American Journal of Surgical Pathology, 2012
- Determining the Site of Origin of Mucinous AdenocarcinomaThe American Journal of Surgical Pathology, 2011
- Immunohistochemical Analysis in a Morphologic Spectrum of Urachal Epithelial NeoplasmsThe American Journal of Surgical Pathology, 2011
- Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid CarcinomaThe American Journal of Surgical Pathology, 2011
- ARID1AMutations in Endometriosis-Associated Ovarian CarcinomasNew England Journal of Medicine, 2010
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell CarcinomaScience, 2010
- Expression of glypican 3 in placental site trophoblastic tumorDiagnostic Pathology, 2010
- Intercepting pelvic cancer in the distal fallopian tube: Theories and realitiesMolecular Oncology, 2009
- A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutationsGynecologic Oncology, 2008